Paragon Advisors LLC Boosts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Paragon Advisors LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,405 shares of the company’s stock after buying an additional 426 shares during the quarter. Paragon Advisors LLC’s holdings in IDEXX Laboratories were worth $1,821,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Private Advisor Group LLC grew its position in shares of IDEXX Laboratories by 8.7% during the 2nd quarter. Private Advisor Group LLC now owns 2,287 shares of the company’s stock valued at $1,114,000 after purchasing an additional 183 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in IDEXX Laboratories during the second quarter worth about $89,000. DekaBank Deutsche Girozentrale increased its stake in IDEXX Laboratories by 3.8% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 54,220 shares of the company’s stock worth $26,721,000 after acquiring an additional 1,963 shares during the last quarter. Zions Bancorporation N.A. raised its holdings in shares of IDEXX Laboratories by 6.7% in the 2nd quarter. Zions Bancorporation N.A. now owns 496 shares of the company’s stock valued at $242,000 after acquiring an additional 31 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of IDEXX Laboratories by 1.0% during the 2nd quarter. Parallel Advisors LLC now owns 2,595 shares of the company’s stock valued at $1,264,000 after acquiring an additional 26 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $418.05 on Monday. The firm has a market cap of $34.23 billion, a price-to-earnings ratio of 40.31, a PEG ratio of 3.94 and a beta of 1.36. The company has a 50-day simple moving average of $423.76 and a two-hundred day simple moving average of $459.98. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.53 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays lowered their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $539.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.